Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586977 | 0.78 | CYP3A4 (0.34) | BRD4SLC6A2SLC6A4SLC6A3CYP1A2 | |
| Hydrochloric Acid SCHEMBL10553606 | 0.76 | — | — | |
| SCHEMBL3593370 | 0.73 | CYP19A1 (0.33) | — | |
| SCHEMBL3587636 | 0.73 | SMN1; SMN2 (0.36) | CYP2C19 | |
| SCHEMBL8307543 | 0.70 | BRD4 (0.46) | BRD4 | |
| SCHEMBL3590039 | 0.70 | ALDH1A1 (0.41) | — | |
| SCHEMBL9396268 | 0.64 | CYP3A4 (0.32) | CYP1A2 | |
| SCHEMBL27899843 | 0.64 | — | — | |
| SCHEMBL12891657 | 0.63 | — | — | |
| SCHEMBL12765089 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728028-B2 | Substituted imidazoline compounds | GRUENENTHAL GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20090048323-A1 | SUBSTITUTED IMIDAZOLINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| US-4853027-A | PREEMGENCE, POSTEMERGENCE HOERBICIDES; WEEDS, GRASSES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048323-A1 | SUBSTITUTED IMIDAZOLINE COMPOUNDS | ITCH, OPRK1, ALDH1A1 | BRD4 1230/4885SLC6A2 355/4885SLC6A4 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.